DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
130.96
+2.65 (+2.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close128.31
Open127.68
Bid130.66 x 1300
Ask133.56 x 3200
Day's Range127.60 - 131.09
52 Week Range42.62 - 131.10
Volume607,759
Avg. Volume985,431
Market Cap11.571B
Beta0.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit16 hours ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of DXCM earnings conference call or presentation 1-Aug-18 8:30pm GMT

    Q2 2018 DexCom Inc Earnings Call

  • Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
    Bloomberg8 days ago

    Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring

    Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.

  • What Does Tandem Diabetes Care’s Valuation Trend Indicate?
    Market Realist10 days ago

    What Does Tandem Diabetes Care’s Valuation Trend Indicate?

    From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.

  • 3 Stocks That Soared 20% or More This Week -- Which Are Still Buys?
    Motley Fool15 days ago

    3 Stocks That Soared 20% or More This Week -- Which Are Still Buys?

    Can the sizzling momentum continue for these hot stocks?

  • DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
    Zacks16 days ago

    DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

    Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

  • Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results
    Market Realist16 days ago

    Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results

    The company released its second-quarter financial results on July 30, and the next day, the stock rose 10.95% to $27.56 from its prior day’s close of $24.84. In the second quarter of 2018, Tandem Diabetes Care’s net revenues grew 60% to $34.1 million compared to $21.3 million in the second quarter of 2017. Tandem Diabetes Care anticipates net revenues in fiscal 2018 to be $140 million–$148 million, which reflects 30%–38% year-over-year growth.

  • DexCom Stock Skyrockets on Q2 Earnings Beat
    InvestorPlace16 days ago

    DexCom Stock Skyrockets on Q2 Earnings Beat

    DexCom’s positive earnings report for the second quarter of the year begins with losses per share of 10 cents. It was also great news for DXCM stock by beating out Wall Street’s losses per share estimate of 18 cents for the period. During the second quarter of the year, DexCom reported net income of $30.20 million.

  • MarketWatch16 days ago

    Dexcom stock surges 30% on better-than-expected revenue results

    DexCom Inc. (DXCM) shares surged nearly 30% in extremely heavy Thursday trade after the company reported a second-quarter revenue beat and narrower-than-expected loss. The company said it had an adjusted loss per share of 10 cents, excluding 48 cents per share in income from an investment in Tandem Diabetes Care as well as interest expense on senior convertible notes. The performance was "particularly notable" because the company's G6 platform -- a new iteration of the device that integrates with a smartphone, has a sensor that lasts 10 days and doesn't require a fingerstick test to measure blood sugar levels -- was only launched late in the quarter, Chief Executive Kevin Sayer noted.

  • Why Dexcom Is Soaring Today
    Motley Fool16 days ago

    Why Dexcom Is Soaring Today

    Traders cheer after the company reports impressive second-quarter results. Here's what investors need to know.

  • Benzinga17 days ago

    The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...

  • What DexCom Just Said About Its Future
    Motley Fool17 days ago

    What DexCom Just Said About Its Future

    Sales momentum for the maker of continuous monitors for diabetes patients could accelerate.

  • Benzinga17 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Cigna Corporation (NYSE: CI ) stock gained nearly ...

  • DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks17 days ago

    DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates

    DexCom (DXCM) delivered earnings and revenue surprises of 50.00% and 18.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press17 days ago

    DexCom: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had net income of 34 cents. Losses, adjusted for investment gains, came to 10 cents per share. The results topped Wall Street expectations. The ...

  • InvestorPlace17 days ago

    5 Connected Devices Stocks for a High-Tech Portfolio

    The market for connected devices has been around for a lot longer than most people think. According to a report from LM Ericsson (NASDAQ:ERIC), the number of connected devices is forecast to hit 29 billion by 2022. While there are many benefits to connected devices, there are also some downsides.

  • How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
    Market Realist19 days ago

    How the Freestyle Libre CGM Opportunity Is Playing Out for ABT

    Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • How Zimmer Biomet’s Product Porfolio Is Positioned
    Market Realist24 days ago

    How Zimmer Biomet’s Product Porfolio Is Positioned

    In the first quarter of this year, Zimmer Biomet’s (ZBH) knee device revenue grew ~1.8% YoY (year-over-year) to $713.3 million from $700.8 million. In the Americas, EMEA (Europe, the Middle East, and Africa), and Asia-Pacific, the knee segment generated revenue of $417.2 million, $188.9 million, and $107.2 million, respectively, reflecting a ~2.5% decline, ~12.4% growth, and ~2.3% growth YoY from $428.0 million, $167.9 million, and $104.9 million.

  • TheStreet.comlast month

    The Three Bullish Charts of DexCom

    With more gains likely on the charts let's come up with a strategy to take advantage of this opportunity.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • TheStreet.comlast month

    Top Analysts Say Gamble On These 3 Ace Stocks

    Here, we turned to TipRanks' Analysts' Top Stocks tool to source the most recommended stocks on Wall Street. The verdict: best-performing analysts across the Street believe these investments will bolster your portfolio. This 'Strong Buy' tech stock has won the attention of five top ranked analysts, who have all recently upgraded their recommendations to Buy.

  • 3 Top Growth Stocks to Buy in July
    Motley Foollast month

    3 Top Growth Stocks to Buy in July

    If you're a growth investor, these stocks are for you.

  • Top Stocks Set to Disrupt the Diabetes Market
    Motley Foollast month

    Top Stocks Set to Disrupt the Diabetes Market

    Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

  • 3 Best Diabetes Stocks of 2018 So Far
    Motley Fool2 months ago

    3 Best Diabetes Stocks of 2018 So Far

    These diabetes stocks gained at least 50% in the first half of the year. But can the momentum continue?